These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11848470)

  • 1. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human HT-29 colon carcinoma and human CaKi1 renal cell carcinoma xenografts.
    Teicher BA; Menon K; Alvarez E; Galbreath E; Shih C; Faul MM
    Anticancer Res; 2001; 21(5):3175-84. PubMed ID: 11848470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts.
    Teicher BA; Menon K; Alvarez E; Liu P; Shih C; Faul MM
    In Vivo; 2001; 15(3):185-93. PubMed ID: 11491013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.
    Teicher BA; Menon K; Alvarez E; Shih C; Faul MM
    Invest New Drugs; 2002 Aug; 20(3):241-51. PubMed ID: 12201487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in murine lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts.
    Teicher BA; Menon K; Alvarez E; Galbreath E; Shih C; Faul MM
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):473-80. PubMed ID: 11800028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts.
    Teicher BA; Menon K; Alvarez E; Galbreath E; Shih C; Faul M
    Clin Cancer Res; 2001 Mar; 7(3):634-40. PubMed ID: 11297259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic effects of a protein kinase Cbeta-selective small molecule.
    Teicher BA; Alvarez E; Menon K; Esterman MA; Considine E; Shih C; Faul MM
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):69-77. PubMed ID: 11855754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
    Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
    Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between cisplatin and gemcitabine in vitro and in vivo.
    Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryptophycin 52 and cryptophycin 55 in sequential and simultaneous combination treatment regimens in human tumor xenografts.
    Teicher BA; Forler P; Menon K; Phares V; Amsrud T; Shih C
    In Vivo; 2000; 14(4):471-80. PubMed ID: 10945160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    Takahashi N; Haba A; Matsuno F; Seon BK
    Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
    Jin K; Lan H; Xie B; He K; Xu Z; Li G; Han N; Teng L; Cao F
    Cancer Biol Ther; 2012 Jul; 13(9):737-44. PubMed ID: 22617773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
    Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
    Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
    O'Reilly T; McSheehy PM; Wartmann M; Lassota P; Brandt R; Lane HA
    Anticancer Drugs; 2011 Jan; 22(1):58-78. PubMed ID: 20890178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antitumor activity of capecitabine in combination with irinotecan.
    Cao S; Durrani FA; Rustum YM
    Clin Colorectal Cancer; 2005 Jan; 4(5):336-43. PubMed ID: 15663838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model.
    Muramaki M; Miyake H; Hara I; Kawabata G; Kamidono S
    J Urol; 2004 Oct; 172(4 Pt 1):1485-9. PubMed ID: 15371876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer.
    Chougule MB; Patel A; Sachdeva P; Jackson T; Singh M
    PLoS One; 2011; 6(11):e27394. PubMed ID: 22102891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo.
    Patras L; Sylvester B; Luput L; Sesarman A; Licarete E; Porfire A; Muntean D; Drotar DM; Rusu AD; Nagy AL; Catoi C; Tomuta I; Vlase L; Banciu M; Achim M
    Cancer Biol Ther; 2017 Aug; 18(8):616-626. PubMed ID: 28696813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.
    Yamamoto K; Mizutani Y; Nakanishi H; Fujiwara J; Ishida H; Toiyama D; Abe K; Hayashi I; Okada K; Kawauchi A; Mizuno M; Yoshida J; Miki T
    Int J Oncol; 2008 Sep; 33(3):565-71. PubMed ID: 18695887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.